Tumor Genetics Are Thrombogenic

Mahé, Isabelle; Scotté, Florian; Elalamy, Ismaı̈l

doi:10.1016/j.jaccao.2023.03.002

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, the occurrence of VTE may indicate aggressive characteristics of the tumor. In a recent study of cancer-associated VTE, somatic mutations of KRAS and STK11 were associated with thromboembolic events [ 48 , 49 ]. However, mutations frequently identified in breast cancer, such as TP53 mutations, did not elevate the risk of VTE [ 48 , 50 ].…”

Section: Discussionmentioning

confidence: 99%

The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience

Park

Ahn

Kwon

et al. 2023

Cancers

View full text Add to dashboard Cite

The relationship between cancer and venous thromboembolism (VTE) has long been described. The risk of VTE in Asian patients with breast cancer remains largely unknown. This study described the incidence and risk factors of VTE in Korean patients with breast cancer. Data were collected from a retrospective database of patients who underwent breast cancer surgery between 2011 and 2020 at a single institution. The Cox proportional-hazards model was used to identify factors associated with VTE occurrences. Among the 2246 patients with breast cancer, 48 (2.1%) developed VTE during a median follow-up period of 53 months. The average incidence of VTE was 459 per 100,000 person-years. Age ≥ 60 years, male sex, chronic kidney disease, reconstructive procedures, and stage II or higher were independent predictive factors for VTE. VTE was associated with poor disease-free survival (hazard ratio (HR), 6.140; 95% confidence interval (CI), 3.480–10.835), and overall survival (HR, 8.842; 95% CI 4.386–17.824). Most VTE events were manageable with anticoagulation; three (6.3%) patients died of VTE, despite intensive care. The incidence of VTE was significantly elevated in Korean patients with breast cancer. Since VTE has a negative effect on oncologic outcomes of breast cancer, clinicians should manage its risk throughout their lifetime.

show abstract